Search - tctmd.com

Displaying 841 - 860 of 868

Sort: Relevancy | Date

News Daily News

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Leah Lawrence

April 26, 2011

News Daily News

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

April 20, 2011

News Daily News

Bleeding Increases Mortality as Late as 3 Years After DES

Leah Lawrence

April 18, 2011

News Daily News

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

L.A. McKeown

April 07, 2011

News Daily News

Vascular Stents an Option for Some Patients with Fibrosing Mediastinitis

March 29, 2011

News Daily News

In Vivo Study Suggests DES Polymer-Drug Coatings Not Inherently Thrombogenic

Caitlin E. Cox

March 25, 2011

News Daily News

Stent Thrombosis, Major Bleeding Rare with Sirolimus-Eluting Stents

March 21, 2011

News Daily News

SYNTAX Analysis: PCI, CABG Offer Substantial Symptom Relief But Timing Differs

Caitlin E. Cox

March 16, 2011

News Daily News

GRAVITAS Published: No Benefit from High-Dose Clopidogrel in Poor Responders

L.A. McKeown

March 15, 2011

News Daily News

Restenosis After Left Main Stenting Does Not Affect Long-term Prognosis

March 14, 2011

News Daily News

IVUS Supports Effectiveness of Novel Stent with Bioabsorbable Polymer

L.A. McKeown

March 10, 2011

News Daily News

Studies Support DES Use in Diabetics, But Results Vary by Device

Caitlin E. Cox

March 08, 2011

News Daily News

Cilostazol Reduces Repeat Revascularizations for Long Lesions

March 06, 2011

News Daily News

Autopsy Study: About One-Third of DES Contain New Atherosclerosis

March 01, 2011

News Daily News

New Dual-Drug DES Adds Cilostazol to Boost Effectiveness of Paclitaxel

Jason Kahn

February 23, 2011

News Daily News

Paclitaxel-Eluting Balloon Effective for DES Restenosis

February 22, 2011

News Daily News

IVUS Study Investigates Mechanisms of DES Restenosis

Jason Kahn

February 06, 2011

News Daily News

Superiority of Xience V Over Taxus in Women Sustained at 3 Years

Leah Lawrence

February 03, 2011

News Daily News

More Than 1 in 10 Patients Discontinue Antiplatelet Therapy Early

L.A. McKeown

January 24, 2011

News Daily News

Randomized Trial Clouds Debate Over DES, CABG in Left Main Disease

Jason Kahn

January 23, 2011

Advertisement

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

Bleeding Increases Mortality as Late as 3 Years After DES

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

Vascular Stents an Option for Some Patients with Fibrosing Mediastinitis

In Vivo Study Suggests DES Polymer-Drug Coatings Not Inherently Thrombogenic

Stent Thrombosis, Major Bleeding Rare with Sirolimus-Eluting Stents

SYNTAX Analysis: PCI, CABG Offer Substantial Symptom Relief But Timing Differs

GRAVITAS Published: No Benefit from High-Dose Clopidogrel in Poor Responders

Restenosis After Left Main Stenting Does Not Affect Long-term Prognosis

IVUS Supports Effectiveness of Novel Stent with Bioabsorbable Polymer

Studies Support DES Use in Diabetics, But Results Vary by Device

Cilostazol Reduces Repeat Revascularizations for Long Lesions

Autopsy Study: About One-Third of DES Contain New Atherosclerosis

New Dual-Drug DES Adds Cilostazol to Boost Effectiveness of Paclitaxel

Paclitaxel-Eluting Balloon Effective for DES Restenosis

IVUS Study Investigates Mechanisms of DES Restenosis

Superiority of Xience V Over Taxus in Women Sustained at 3 Years

More Than 1 in 10 Patients Discontinue Antiplatelet Therapy Early

Randomized Trial Clouds Debate Over DES, CABG in Left Main Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content